Vycellix
Vycellix is a private, immuno-centric discovery life science company focused on developing next-generation cell & gene-based therapies, including T cell and natural killer (NK) cell-based cancer therapies. Their mission is to deliver best-in-class allogeneic cell-based therapies while eliminating immune rejection, utilizing innovative platform technologies such as VY-UC, VY-X, VY-M, VY-OZ, and VY-GAGE. The company collaborates with leading research institutions like Karolinska Institutet and Moffitt Cancer Center, and is involved in advancing off-the-shelf, immune-privileged cell therapies for cancer treatment.
Industries
Nr. of Employees
small (1-50)
Vycellix
3000 North Military Trail, Suite 103, Boca Raton, FL 33431
Patents
RNA construct and methods of use thereof for enhancing the therapeutic effects of cytotoxic cells and stem cells
US-12128061-B2
View Details
RNA construct and methods of use thereof for enhancing the therapeutic effects of cytotoxic cells and stem cells
US-12128061-B2
View DetailsProducts
Universal allogeneic cell engineering platform (membrane‑anchored immune synapse blocker)
A single‑transgene, membrane‑anchored engineering approach designed to prevent functional immune synapse formation between host immune cells and donor grafts, applied across donor cell types to create immune‑privileged allogeneic cells without HLA gene‑editing.
Effector cell potency enhancement construct (RNA‑based)
RNA‑based constructs intended to increase intracellular loading of cytolytic granules in cytotoxic effector cells to enhance serial killing capacity and tumor cell clearance.
Multi‑antigen engager delivery platform (membrane‑embedded payloads)
Construct and membrane‑embedded delivery approach to encode and deliver multiple disease‑targeting payloads selectively to tumor microenvironments, enabling local deployment of bispecific engager‑type molecules and CAR payloads to improve tumor targeting and safety.
Gene transduction and CRISPR‑editing enhancement reagent and platform
Methods and reagents for improving viral vector transduction into primary and engineered cells combined with agents that increase CRISPR‑mediated gene‑editing efficiency for adoptive cell therapies.
Cell expansion and manufacturing platform
Process and platform technologies to accelerate expansion of therapeutic cell populations to support development and potential clinical supply.
Universal allogeneic cell engineering platform (membrane‑anchored immune synapse blocker)
A single‑transgene, membrane‑anchored engineering approach designed to prevent functional immune synapse formation between host immune cells and donor grafts, applied across donor cell types to create immune‑privileged allogeneic cells without HLA gene‑editing.
Effector cell potency enhancement construct (RNA‑based)
RNA‑based constructs intended to increase intracellular loading of cytolytic granules in cytotoxic effector cells to enhance serial killing capacity and tumor cell clearance.
Multi‑antigen engager delivery platform (membrane‑embedded payloads)
Construct and membrane‑embedded delivery approach to encode and deliver multiple disease‑targeting payloads selectively to tumor microenvironments, enabling local deployment of bispecific engager‑type molecules and CAR payloads to improve tumor targeting and safety.
Gene transduction and CRISPR‑editing enhancement reagent and platform
Methods and reagents for improving viral vector transduction into primary and engineered cells combined with agents that increase CRISPR‑mediated gene‑editing efficiency for adoptive cell therapies.
Cell expansion and manufacturing platform
Process and platform technologies to accelerate expansion of therapeutic cell populations to support development and potential clinical supply.
Services
Joint research collaborations with academic centers and technology partners to advance discovery‑stage cell engineering solutions, validate preclinical candidates, and optimize manufacturing approaches.
Design and execution of in vitro and in vivo studies to evaluate persistence, function, immune evasion and anti‑tumor activity of engineered cell products to support progression toward clinical evaluation.
Business development to identify commercial partners and license platform technologies for therapeutic and platform applications.
Joint research collaborations with academic centers and technology partners to advance discovery‑stage cell engineering solutions, validate preclinical candidates, and optimize manufacturing approaches.
Design and execution of in vitro and in vivo studies to evaluate persistence, function, immune evasion and anti‑tumor activity of engineered cell products to support progression toward clinical evaluation.
Business development to identify commercial partners and license platform technologies for therapeutic and platform applications.
Expertise Areas
- Allogeneic cell therapy development
- Natural killer (NK) and T cell therapeutics
- Cell engineering for immune evasion
- Gene delivery, viral transduction and gene‑editing enhancement
Key Technologies
- Membrane‑anchored immune synapse‑blocking transgenes
- Small‑molecule ex vivo transduction and gene‑editing enhancers
- Membrane‑embedded multi‑payload engagers/peptides for localized delivery
- Small non‑coding RNA constructs to increase cytolytic granule loading
News & Updates
Proof-of-concept data reported for new multi-antigen engager platform (VY-GAGE) designed to overcome solid tumor defense mechanisms. Single-step CD45 allogeneic cell engineering platform (VY-UC) shown to offer significant benefits as an alternative to complex gene-editing systems. Vycellix presented new data at NK2023 in Oslo, Norway, highlighting proprietary platforms to optimize cell therapy manufacturing and outcomes.
Vycellix announced proof-of-concept results for its VY-UC platform, which engineers immune-privileged cells without complex gene-editing, potentially transforming off-the-shelf cell therapies.
Proof-of-concept data reported for new multi-antigen engager platform (VY-GAGE) designed to overcome solid tumor defense mechanisms. Single-step CD45 allogeneic cell engineering platform (VY-UC) shown to offer significant benefits as an alternative to complex gene-editing systems. Vycellix presented new data at NK2023 in Oslo, Norway, highlighting proprietary platforms to optimize cell therapy manufacturing and outcomes.
Vycellix announced proof-of-concept results for its VY-UC platform, which engineers immune-privileged cells without complex gene-editing, potentially transforming off-the-shelf cell therapies.